drugset / Trial / NCT02168829
Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
Phase 4
Completed
1284 enrolled
Ottawa Heart Institute Research Corporation
Abbott · collabBayer · collabBiotronik Canada Inc · collabCanadian Institutes of Health Research (CIHR) · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia. AF is normally associated with an increased risk of stroke which in many patients can be prevented with appropriate blood thinner therapy. This trial will compare a strategy of oral anticoagulant therapy after successful ablation to therapy with an aspirin per day.
Timeline
- Start
- 2016-01
- Primary completion
- 2025-08-14
- Completion
- 2025-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aspirin | Small molecule | — | — |
| Comparator | Rivaroxaban | Other / unclassified | 15 mg | Oral |